Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03540745 · ClinicalTrials.gov registry record · NA
Nexalin Therapy as a Viable Adjunctive Treatment for Substance Use Disorders
A NA study of Depression and Anxiety, sponsored by University of Arizona.
- Active
- Registry status
- NA
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT03540745: Active NA study of Depression and Anxiety, sponsored by University of Arizona.
NCT03540745 is a NA study of Depression and Anxiety that is active but no longer recruiting, run by University of Arizona. The registered enrollment target is 14 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03540745, a NA study of Depression and Anxiety, is active but no longer recruiting, sponsored by University of Arizona.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to determine whether Nexalin Trans-cranial Electrical Stimulation (TES) is a viable adjunctive treatment of substance use treatments.
Primary Outcome
Reduction in depressive symptoms as a result of Nexalin vs Sham
Conditions Studied
Interventions
- DEVICE TES Treatment
- DEVICE TES-SHAM Treatment
Study Locations (1)
New Jersey
- Carrier Clinic - Belle Mead
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2018-06-11 |
| Est. Completion | 2019-11 |
| Phase | NA |
What the registry record for NCT03540745 still lists
NCT03540745 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (98% lower).
The record links to 4 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which TES Treatment is the first listed.
NCT03540745 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT03540745 about?
NCT03540745 is a clinical study titled "Nexalin Therapy as a Viable Adjunctive Treatment for Substance Use Disorders". The purpose of this research study is to determine whether Nexalin Trans-cranial Electrical Stimulation (TES) is a viable adjunctive treatment of substance use treatments.
What is the current status of trial NCT03540745?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 14 participants. The study started on 2018-06-11. Estimated completion is 2019-11.
What conditions does trial NCT03540745 study?
This clinical trial studies the following conditions: Depression, Anxiety, Insomnia, Substance Abuse.
What interventions are being tested in trial NCT03540745?
The interventions under investigation include: TES Treatment (DEVICE), TES-SHAM Treatment (DEVICE).
Who is sponsoring clinical trial NCT03540745?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03540745 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03540745's enrollment target sits among peer trials
14 648th of 679 higher than 30 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reaching Out to Distressed Medical Residents, Fellows and Faculty
RECRUITING · NA
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
Cold and Heat Investigation to Lower Levels of Depression
RECRUITING · NA
-
Dosing rTMS for Depression Post-SCI
RECRUITING · NA
-
Exploring Virtual Reality Adventure Training Exergaming
RECRUITING · NA
-
Brief Interventions for Coping with Distress
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
- NCT05183048 · 14 participants · Early Phase 1
Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy